Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing Business of Bureau Veritas
The transaction will create a business with $1bn in revenue, significantly reinforcing Mérieux NutriSciences' position as a global leader in food testing, inspection, and certification (TIC). It expands Mérieux NutriSciences' geographic footprint, doubling its presence in Asia Pacific and Canada, and providing access to new regions with considerable growth potential. ...
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting
SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting...
Alpha Asia Aesthetics: an Instagram-Worthy Aesthetic Clinic Launched in Partnership with Entrepreneur Investor Ivan Lee
SINGAPORE, Oct. 7, 2024 /PRNewswire/ -- Influencer doctor Dr Jeanel Goh and the famed founder of Thai Express, Mr Ivan Lee, have come together to leave their mark on Singapore's Aesthetic Medicine scene with their brainchild: Alpha Asia Aesthetics. Leveraging on Dr Jeanel's experience working in an international aesthetic chain for over six years and Mr Lee's keen financial acumen,...
Medinol Announces Successful First-in-Human Implantation of ChampioNIR Drug-Eluting Peripheral Stent System in Australia
TEL AVIV, Israel, Oct. 7, 2024 /PRNewswire/ -- Medinol Ltd. is pleased to announce the successful First-in-Human (FIH) implantation of the ChampioNIR Drug-Eluting Peripheral Stent by Drs Gerard S.Goh and Thodur Vasudevan of the Alfred Hospital in Melbourne Australia, introducing a revolutionary advancement in the mechanics, durability and drug delivery of peripheral...
PROMISING CELL THERAPY OFFERS HOPE FOR RELAPSED OR REFRACTORY T-CELL LEUKAEMIA
Fratricide-resistant CD7 CAR-T therapy by NUS proves effective in treating relapsed or refractory T-cell leukaemia SINGAPORE, Oct. 5, 2024 /PRNewswire/ -- A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment options. Published in...
Cyient DLM Expands Global Footprint with Strategic Acquisition of US-Based EMS Manufacturer
HYDERABAD, India, Oct. 4, 2024 /PRNewswire/ -- Cyient DLM, a leading integrated electronics manufacturing company, announced today its acquisition of Altek Electronics, a prominent EMS (Electronic Manufacturing Services) company based in the United States. This strategic move marks a significant milestone in Cyient DLM's growth plan, expanding its presence in the North American market and strengthening its capabilities across...
TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218
TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) The first patient with head and neck squamous cell carcinoma was dosed in the Phase 2a clinical trial of TU2218 The Phase 2a trial of TU2218 starts...
Clarivate in partnership with Abiquifi Announces Annual Summit LATAM Agenda
Top industry leaders to explore AI, data, strategic partnerships, and innovation opportunities in Latin America at premier Life Sciences event LONDON, Oct. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, today announced the full agenda for the 2nd annual Summit LATAM, which will be held in...
Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development
HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, announced that the Company has entered into a subscription agreement with Dr. Poon Hung Fai ("Dr. Poon"), the subscriber. Dr....
ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
- MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio's ABL103 in a Phase 1b/2 clinical trial SEONGNAM, South Korea, Oct. 4, 2024 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a clinical trial collaboration and...
